Universal Biosensors

Universal Biosensors Inc (UBI) is a global biosensor company and a world leader in electrochemical cell technology. UBI’s ambition is to utilize its patented biosensor technology to develop a diverse range of biosensor test strips used in our hand-held portable analyzers; for cost effective, effortless, and accurate detection of analytes of interest, within many industries including human health, animal health, environmental, and agriculture. UBI is a USA Delaware company listed on the Australian Securities Exchange (ASX:UBI) and operates from its head office, manufacturing facility, and research laboratory in Melbourne, Victoria, Australia.

In 2021, UBI successfully launched its unique handheld wine analyzer called Sentia™ to test and measure six assays, routinely performed in the wine production process. In 2022, UBI launched Xprecia Prime™ in the EU and UK, the next-generation blood coagulation analyzer which replaces Xprecia Stride®. Xprecia Prime™ launched in the US in 2024 following a successful FDA 510(k) approval and CLIA waiver. UBI launched PETRACKR® in May 2023, a veterinary blood glucometer to monitor diabetes in cats and dogs. These products will complement UBI’s existing Canadian blood testing laboratory Hemostasis Reference Lab (HRL).